KR950703365A - 플루오레신 유도체의 안정한 고농축 제형(Stable highly concentrated formulations of fluorescein derivatives) - Google Patents
플루오레신 유도체의 안정한 고농축 제형(Stable highly concentrated formulations of fluorescein derivatives) Download PDFInfo
- Publication number
- KR950703365A KR950703365A KR1019950700947A KR19950700947A KR950703365A KR 950703365 A KR950703365 A KR 950703365A KR 1019950700947 A KR1019950700947 A KR 1019950700947A KR 19950700947 A KR19950700947 A KR 19950700947A KR 950703365 A KR950703365 A KR 950703365A
- Authority
- KR
- South Korea
- Prior art keywords
- fluorescein
- cyclodextrin
- hydroxypropyl
- formulation
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92810695.4 | 1992-09-10 | ||
| EP92810695 | 1992-09-10 | ||
| PCT/EP1993/002367 WO1994005331A1 (de) | 1992-09-10 | 1993-09-02 | Stabile hochkonzentrierte formulierungen von fluoresceinderivaten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR950703365A true KR950703365A (ko) | 1995-09-20 |
Family
ID=8211984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950700947A KR950703365A (ko) | 1992-09-10 | 1993-09-02 | 플루오레신 유도체의 안정한 고농축 제형(Stable highly concentrated formulations of fluorescein derivatives) |
Country Status (9)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7390668B2 (en) * | 1996-10-30 | 2008-06-24 | Provectus Pharmatech, Inc. | Intracorporeal medicaments for photodynamic treatment of disease |
| US8557298B2 (en) | 1998-08-06 | 2013-10-15 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
| US7026166B2 (en) * | 2002-01-22 | 2006-04-11 | Chiron Corporation | Fluorogenic dyes |
| US7704756B2 (en) * | 2003-01-21 | 2010-04-27 | Novartis Vaccines And Diagnostics, Inc. | Fluorogenic dyes |
| EP1638508B1 (en) * | 2003-06-16 | 2014-08-13 | Solx, Inc. | Shunt for the treatment of glaucoma |
| EP1715799A4 (en) * | 2004-01-22 | 2010-06-02 | Solx Inc | METHOD FOR TREATING GLAUCOMA |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| FR2611141B1 (fr) * | 1987-02-20 | 1991-02-01 | Int Rech Cancer Centre | Ensemble ou kit pour utilisation comme agent pour la destruction selective de cellules transformees ou tumorales |
| US5227372A (en) * | 1990-03-07 | 1993-07-13 | Children's Medical Center Corporation | Method for retaining ophthalmological agents in ocular tissues |
-
1992
- 1992-09-19 TW TW081107414A patent/TW251236B/zh active
-
1993
- 1993-09-02 CA CA002143115A patent/CA2143115A1/en not_active Abandoned
- 1993-09-02 KR KR1019950700947A patent/KR950703365A/ko not_active Application Discontinuation
- 1993-09-02 EP EP93919243A patent/EP0663838A1/de not_active Ceased
- 1993-09-02 AU AU49561/93A patent/AU4956193A/en not_active Abandoned
- 1993-09-02 JP JP6506874A patent/JPH08503928A/ja active Pending
- 1993-09-02 WO PCT/EP1993/002367 patent/WO1994005331A1/de not_active Application Discontinuation
- 1993-09-02 US US08/392,993 patent/US5573773A/en not_active Expired - Fee Related
-
1995
- 1995-03-08 FI FI951092A patent/FI951092A/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US5573773A (en) | 1996-11-12 |
| WO1994005331A1 (de) | 1994-03-17 |
| AU4956193A (en) | 1994-03-29 |
| TW251236B (US20100012521A1-20100121-C00001.png) | 1995-07-11 |
| EP0663838A1 (de) | 1995-07-26 |
| FI951092A0 (fi) | 1995-03-08 |
| FI951092A (fi) | 1995-03-08 |
| JPH08503928A (ja) | 1996-04-30 |
| CA2143115A1 (en) | 1994-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU724799B2 (en) | Pharmaceutical formulations containing voriconazole | |
| FI86140C (fi) | Foerfarande foer framstaellning av en farmaceutisk beredning som innehaoller ett i vatten svaorloesligt eller i vatten instabilt laekemedel. | |
| Usayapant et al. | Effect of 2-hydroxypropyl-β-cyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate | |
| US5403858A (en) | New compositions containing taxane derivatives | |
| US5631297A (en) | Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same | |
| ES2193658T3 (es) | Procedimiento para la preparacion de formulaciones acuosas para uso oftalmico. | |
| RU96108776A (ru) | Преоральные противогрибковые композиции | |
| US4278654A (en) | Process for the preparation of a sterile injectable physiologically acceptable solution of an X-ray contrast agent and solutions of the X-ray contrast agent and a buffer | |
| EP0435682A2 (en) | The use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension | |
| JPH02706A (ja) | 水性医薬製剤 | |
| PL195280B1 (pl) | Kompleks inhibitora RAS-farnezylotransferazy o ulepszonej rozpuszczalności w wodzie i trwałości oraz kompozycja inhibitora RAS-farnezylotransferazy | |
| KR950703365A (ko) | 플루오레신 유도체의 안정한 고농축 제형(Stable highly concentrated formulations of fluorescein derivatives) | |
| JP5325779B2 (ja) | 医薬組成物 | |
| Yang et al. | Preparation of water-soluble altrenogest inclusion complex with β-cyclodextrin derivatives and in vitro sustained-release test | |
| FR2598081A1 (fr) | Procede de preparation d'une solution pharmaceutique aqueuse d'un principe actif constitue par un acide organique | |
| CA1129772A (en) | Stable erythromycin solution | |
| HU198839B (en) | Process for producing aqueous compositions comprising hydroxy-alkadiinyl-benzoquinone derivatives as active ingredient | |
| WO2018042363A1 (en) | Pharmaceutical formulations of regadenoson | |
| JPH10512549A (ja) | 可溶性の２−クロロ−２’−デオキシアデノシン配合物 | |
| JPH07157431A (ja) | 安定なプロスタグランジンｅ製剤 | |
| CA2016911A1 (en) | Hypoallergenic steroidal anesthetic/hypnotic compositions | |
| FI915570A0 (fi) | Inklusionskomplex av 3 -morfolinosydnonimin eller dess salter eller dess tautomera isomerer, foerfarande foer deras framstaellning och farmaceutiska kompositioner innehaollande desamma. | |
| CA2183367C (fr) | Collyre a base d'indometacine pret a l'emploi | |
| JP2001261559A (ja) | 高濃度ビタミンｃ組成物及びその調製方法 | |
| US4774250A (en) | Composition and method for treating differentiated carcinoma or melanoma cells with thiapyrylium dyes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |